Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma

OBJECTIVE: Gemcitabine plus nab-paclitaxel (GnP) is the standard first-line therapy for advanced pancreatic ductal adenocarcinoma (PDAC). S-1, an oral fluoropyrimidine derivative, as compared with gemcitabine, is non-inferior in terms of overall survival (OS) and is associated with lower hematologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Zhou, Tang, Hui, Ying, Jinrong, Cheng, Yuejuan, Wang, Xiang, Wang, Yingyi, Bai, Chunmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618946/
https://www.ncbi.nlm.nih.gov/pubmed/37646237
http://dx.doi.org/10.20892/j.issn.2095-3941.2023.0189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618946/
https://www.ncbi.nlm.nih.gov/pubmed/37646237
http://dx.doi.org/10.20892/j.issn.2095-3941.2023.0189

Ejemplares similares